Leśniak Wiktoria, Bała Małgorzata M, Płaczkiewicz-Jankowska Ewa, Topór-Mądry Roman, Jankowski Miłosz, Sieradzki Jacek, Banasiak Waldemar
2nd Department of Inter nal Medicine, Jagiellonian Univer sity Medical College, Krakow, Poland.
Cardiol J. 2015;22(2):150-9. doi: 10.5603/CJ.a2014.0067. Epub 2014 Oct 9.
ARETAEUS 1 study showed that a great majority of patients with type 2 diabetes mellitus (T2DM) of short duration did not meet all of the treatment goals. Since then the treatment goals in T2DM have been changed. The aim of the ARETAEUS 2-Grupa Study was to assess cardiovascular (CV) risk management and meeting treatment goals in the population of T2DM of more than 10-year duration.
ARETAEUS2-Grupa was a cross-sectional questionnaire-based study conducted in Poland in 2012. Randomly selected physicians recruited 1,740 patients with T2DM diagnosed more than 10 years before the study.
Lipid treatment goals were met respectively: for total cholesterol in 34.5% of all patients, triglycerides in 53.8%, low density lipoprotein cholesterol (LDL-C) in 26.5% and high density lipoprotein cholesterol (HDL-C) in 38.2%. Most of patients with and without coronary artery disease were receiving aspirin (90.3% and 60%, respectively) and statins (84.4% and 67.7%, respectively). The current blood pressure (BP) goal (140/90 mm Hg) was met in 43.5% of patients and the previous goal (< 130/80 mm Hg) in 12.4%. The patients were mainly treated with ≥ 3 antihypertensive drugs. All treatment goals (for HbA1c, BP and LDL-C) were reached only by 8.2% of patients, any two goals by 26.3% of patients, one goal by 39.8% of patients, none by 25.6% of patients.
The new less restrictive treatment goals are reached more frequently but still much is to be done in the field of clinical practice guidelines implementation and CV prevention in T2DM population.
阿雷泰乌斯1研究表明，大多数病程较短的2型糖尿病（T2DM）患者未能达到所有治疗目标。自那时起，T2DM的治疗目标已发生改变。阿雷泰乌斯2 - Grupa研究的目的是评估病程超过10年的T2DM人群的心血管（CV）风险管理及治疗目标达成情况。
阿雷泰乌斯2 - Grupa是2012年在波兰开展的一项基于问卷的横断面研究。随机选取的医生招募了1740例在研究前10年以上被诊断为T2DM的患者。
脂质治疗目标达成情况分别为：总胆固醇在所有患者中的达标率为34.5%，甘油三酯为53.8%，低密度脂蛋白胆固醇（LDL - C）为26.5%，高密度脂蛋白胆固醇（HDL - C）为38.2%。大多数有和没有冠状动脉疾病的患者都在服用阿司匹林（分别为90.3%和60%）和他汀类药物（分别为84.4%和67.7%）。当前血压（BP）目标（140/90 mmHg）在43.5%的患者中达成，之前的目标（<130/80 mmHg）在12.4%的患者中达成。患者主要使用≥3种抗高血压药物进行治疗。所有治疗目标（糖化血红蛋白、血压和LDL - C）仅在8.2%的患者中达成，任意两个目标在26.3%的患者中达成，一个目标在39.8%的患者中达成，无目标达成在25.6%的患者中。
新的限制较少的治疗目标达成得更为频繁，但在T2DM人群的临床实践指南实施和CV预防领域仍有许多工作要做。
